$TPST
Tempest Therapeutics, Inc. Stock $tpst

$tpst Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000162828022022788 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.798M	$3.123M	$3.052M
YoY Change	-9.92%	22.18%	98.83%
% of Gross Profit
Research & Development	$5.973M	$5.651M	$5.109M
YoY Change	29.01%	33.62%	42.23%
% of Gross Profit
Depreciation & Amortization	$201.0K	$112.0K	$108.0K
YoY Change	87.85%	30.23%	38.46%
% of Gross Profit
Operating Expenses	$5.973M	$5.651M	$5.109M
YoY Change	29.01%	33.62%	42.23%
Operating Profit	-$8.771M	-$8.774M	-$8.161M
YoY Change	-213.38%	29.31%	59.18%
Interest Expense	$389.0K	$464.0K	$333.0K
YoY Change	-10.98%	68.12%	44.16%
% of Operating Profit
Other Income/Expense, Net	-$176.0K	-$394.0K	-$330.0K
YoY Change	-52.94%	44.32%	44.74%
Pretax Income	-$8.947M	-$9.168M	-$8.491M
YoY Change	10.32%	29.9%	58.56%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$8.947M	-$9.168M	-$8.491M
YoY Change	10.32%	29.9%	58.56%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.66	-$0.79	-$1.18
Diluted Earnings Per Share	-$0.66	-$0.79	-$1.18
COMMON SHARES
Basic Shares Outstanding	10.42M shares	11.57M shares	7.167M shares
Diluted Shares Outstanding	13.64M shares	11.57M shares	7.167M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$42.79M	$51.62M	$45.75M
YoY Change	-28.34%	-24.55%	-12.46%
Cash & Equivalents	$42.79M	$51.62M	$45.75M
Short-Term Investments
Other Short-Term Assets	$935.0K	$778.0K	$691.0K
YoY Change	33.38%	-62.61%	-62.71%
Inventory
Prepaid Expenses	$998.0K	$305.0K	$643.0K
Receivables
Other Receivables
Total Short-Term Assets	$60.26M	$68.31M	$62.71M
YoY Change	-3.68%	-3.1%	-9.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$919.0K	$1.011M	$1.024M
YoY Change	-17.65%	-79.33%	-8.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$683.0K	$480.0K	$480.0K
YoY Change	509.82%	328.57%	332.43%
Total Long-Term Assets	$2.914M	$3.044M	$4.243M
YoY Change	-36.44%	-39.16%	-0.75%
TOTAL ASSETS
Total Short-Term Assets	$60.26M	$68.31M	$62.71M
Total Long-Term Assets	$2.914M	$3.044M	$4.243M
Total Assets	$63.17M	$71.35M	$66.95M
YoY Change	-5.91%	-5.49%	-8.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$925.0K	$1.448M	$684.0K
YoY Change	-61.13%	-78.37%	-30.98%
Accrued Expenses	$2.585M	$2.186M	$3.234M
YoY Change	55.91%	-28.59%	103.52%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.500M	$2.000M
YoY Change
Total Short-Term Liabilities	$24.06M	$22.42M	$20.82M
YoY Change	287.86%	128.95%	3.94%
LONG-TERM LIABILITIES
Long-Term Debt	$11.84M	$13.30M	$15.13M
YoY Change	-21.12%	-10.82%	0.42%
Other Long-Term Liabilities	$503.0K	$695.0K	$1.648M
YoY Change	-79.02%	-74.01%	11.2%
Total Long-Term Liabilities	$11.84M	$13.30M	$15.13M
YoY Change	-21.12%	-24.38%	0.42%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.06M	$22.42M	$20.82M
Total Long-Term Liabilities	$11.84M	$13.30M	$15.13M
Total Liabilities	$36.40M	$36.42M	$37.60M
YoY Change	54.19%	33.0%	1.28%
SHAREHOLDERS EQUITY
Retained Earnings	-$126.7M	-$117.7M	-$108.6M
YoY Change	37.26%		8.49%
Common Stock	$10.00K	$10.00K	$7.000K
YoY Change	42.86%		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$26.77M	$34.93M	$29.36M
YoY Change
Total Liabilities & Shareholders Equity	$63.17M	$71.35M	$66.95M
YoY Change	-5.91%	-5.49%	-8.58%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$8.947M	-$9.168M	-$8.491M
YoY Change	10.32%	29.9%	58.56%
Depreciation, Depletion And Amortization	$201.0K	$112.0K	$108.0K
YoY Change	87.85%	30.23%	38.46%
Cash From Operating Activities	-$9.072M	-$8.414M	-$7.107M
YoY Change	-23.05%	-6725.2%	12.63%
INVESTING ACTIVITIES
Capital Expenditures	-$108.0K	-$95.00K	$3.000K
YoY Change	350.0%	35.71%	-78.57%
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change	-100.0%
Cash From Investing Activities	-$108.0K	-$95.00K	-$3.000K
YoY Change	-871.43%	35.71%	-78.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$1.403M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	350.0K	14.38M	$1.403M
YoY Change	-88.95%	-64.9%	-90.61%
NET CHANGE
Cash From Operating Activities	-9.072M	-8.414M	-$7.107M
Cash From Investing Activities	-108.0K	-95.00K	-$3.000K
Cash From Financing Activities	350.0K	14.38M	$1.403M
Net Change In Cash	-8.830M	5.867M	-$5.707M
YoY Change	2.58%	-85.7%	-51.68%
FREE CASH FLOW
Cash From Operating Activities	-$9.072M	-$8.414M	-$7.107M
Capital Expenditures	-$108.0K	-$95.00K	$3.000K
Free Cash Flow	-$8.964M	-$8.319M	-$7.110M
YoY Change	-23.81%	-4322.84%	12.43%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001544227
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-35890
	dei	Entity Registrant Name EntityRegistrantName	Tempest Therapeutics, Inc.
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	949000	usd
CY2022Q2	tpst	Prepaid Research And Development Costs Current PrepaidResearchAndDevelopmentCostsCurrent	603000	usd
CY2021Q4	tpst	Prepaid Research And Development Costs Current PrepaidResearchAndDevelopmentCostsCurrent	632000	usd
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	778000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	553000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1686000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2134000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2055000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1937000	usd
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-1472564
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7000 Shoreline Court, Suite 275
	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco,
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
	dei	City Area Code CityAreaCode	(415)
	dei	Local Phone Number LocalPhoneNumber	798-8589
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	TPST
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10418856	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51621000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51829000	usd
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	15000000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	15000000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1686000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2134000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	68307000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	68963000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1011000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1113000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1553000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3051000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	480000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	111000	usd
CY2022Q2	us-gaap	Assets Assets	71351000	usd
CY2021Q4	us-gaap	Assets Assets	73238000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1448000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	991000	usd
CY2022Q2	us-gaap	Litigation Reserve Current LitigationReserveCurrent	15000000	usd
CY2021Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	15000000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2186000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1589000	usd
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent	2000000	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1050000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1442000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	638000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	912000	usd
CY2022Q2	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	101000	usd
CY2021Q4	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	92000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	22423000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20026000	usd
CY2022Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	524000	usd
CY2021Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	756000	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	13301000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	15069000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	695000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2026000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	36419000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	37121000	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10325359	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10325359	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6910324	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6910324	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	10000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	7000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	152644000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	136173000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-117722000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-100063000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	34932000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	36117000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	71351000	usd
	tpst	Stockholders Equity Note Stock Split Exchange Ratio StockholdersEquityNoteStockSplitExchangeRatio	0.0322
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	73238000	usd
CY2022Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	5651000	usd
CY2021Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4229000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	10760000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	7821000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3123000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2556000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6175000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4091000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8774000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6785000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-16935000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11912000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	464000	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	276000	usd
	us-gaap	Interest Expense InterestExpense	797000	usd
	us-gaap	Interest Expense InterestExpense	507000	usd
CY2022Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	70000	usd
CY2021Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	3000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	73000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	6000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-394000	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-273000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-724000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-501000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-9168000	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-7058000	usd
	us-gaap	Profit Loss ProfitLoss	-17659000	usd
	us-gaap	Profit Loss ProfitLoss	-12413000	usd
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.79
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.63
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.63
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.88
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.88
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-17.30
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-17.30
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11573432	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11573432	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	925432	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	925432	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9382515	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9382515	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	717618	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	717618	shares
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	29357000	usd
CY2022Q2	tpst	Stock Issuance Costs StockIssuanceCosts	343000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7095000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	367000	usd
CY2022Q2	tpst	Warrant Issuance Costs WarrantIssuanceCosts	283000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	7281000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-9168000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	34932000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-73951000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	29000	usd
CY2021Q2	tpst	Vesting Of Early Exercised Stock Options And Restricted Stock VestingOfEarlyExercisedStockOptionsAndRestrictedStock	39000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	86707000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	30010000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	411000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	18001000	usd
CY2021Q2	tpst	Adjustments To Additional Paid In Capital Reverse Recapitalization Transaction Costs AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts	6074000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-7058000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	48114000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	36117000	usd
	tpst	Stock Issuance Costs StockIssuanceCosts	387000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8498000	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	695000	usd
	tpst	Warrant Issuance Costs WarrantIssuanceCosts	283000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	7281000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17659000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	34932000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-68793000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	49000	usd
	tpst	Vesting Of Early Exercised Stock Options And Restricted Stock VestingOfEarlyExercisedStockOptionsAndRestrictedStock	96000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	86707000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	30010000	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	531000	usd
	tpst	Adjustments To Additional Paid In Capital Reverse Recapitalization Transaction Costs AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts	6074000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	18001000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12413000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	48114000	usd
	us-gaap	Profit Loss ProfitLoss	-17659000	usd
	us-gaap	Profit Loss ProfitLoss	-12413000	usd
	us-gaap	Depreciation Depreciation	220000	usd
	us-gaap	Depreciation Depreciation	165000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	695000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	531000	usd
	tpst	Noncash Lease Expense NoncashLeaseExpense	613000	usd
	tpst	Noncash Lease Expense NoncashLeaseExpense	274000	usd
	tpst	Noncash Interest And Other Expense Net NoncashInterestAndOtherExpenseNet	232000	usd
	tpst	Noncash Interest And Other Expense Net NoncashInterestAndOtherExpenseNet	286000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-447000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-987000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	438000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	5445000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	323000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1197000	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	9000	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	89000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-839000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-350000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15521000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6183000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	98000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	84000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-98000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-84000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8498000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	30010000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	7281000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	15000000	usd
	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	0	usd
	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	93000	usd
	tpst	Proceeds From Merger Related Cost Financing Activities ProceedsFromMergerRelatedCostFinancingActivities	0	usd
	tpst	Proceeds From Merger Related Cost Financing Activities ProceedsFromMergerRelatedCostFinancingActivities	17045000	usd
	tpst	Payment Of Reverse Recapitalization Transaction Costs PaymentOfReverseRecapitalizationTransactionCosts	0	usd
	tpst	Payment Of Reverse Recapitalization Transaction Costs PaymentOfReverseRecapitalizationTransactionCosts	-6074000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	17000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15779000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55905000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	160000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	49638000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51829000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18820000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51989000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	68458000	usd
	us-gaap	Interest Paid Net InterestPaidNet	556000	usd
	us-gaap	Interest Paid Net InterestPaidNet	383000	usd
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	884000	usd
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	usd
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	4000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	usd
	tpst	Vesting Of Early Exercise Stock Options VestingOfEarlyExerciseStockOptions	0	usd
	tpst	Vesting Of Early Exercise Stock Options VestingOfEarlyExerciseStockOptions	95000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	30000000	usd
CY2021Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-15
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5365899	shares
CY2021Q2	tpst	Business Combination Exchange Ratio BusinessCombinationExchangeRatio	0.0322
	tpst	Stockholders Equity Note Stock Split Exchange Ratio StockholdersEquityNoteStockSplitExchangeRatio	0.0322
	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to research and development accruals, recoverability of long-lived assets, right-of-use assets, lease obligations, stock-based compensation and income taxes uncertainties and valuation allowances. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates.</span>
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	305000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	949000	usd
CY2022Q2	tpst	Prepaid Research And Development Costs Current PrepaidResearchAndDevelopmentCostsCurrent	603000	usd
CY2021Q4	tpst	Prepaid Research And Development Costs Current PrepaidResearchAndDevelopmentCostsCurrent	632000	usd
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	778000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	553000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1686000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2134000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1937000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1044000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	824000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1011000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1113000	usd
CY2022Q2	us-gaap	Depreciation Depreciation	112000	usd
	us-gaap	Depreciation Depreciation	220000	usd
CY2021Q2	us-gaap	Depreciation Depreciation	86000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1317000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1044000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	824000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1011000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1113000	usd
CY2022Q2	us-gaap	Depreciation Depreciation	112000	usd
	us-gaap	Depreciation Depreciation	220000	usd
CY2021Q2	us-gaap	Depreciation Depreciation	86000	usd
	us-gaap	Depreciation Depreciation	165000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1317000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	748000	usd
CY2022Q2	tpst	Accrued Clinical Trial Liability AccruedClinicalTrialLiability	869000	usd
CY2021Q4	tpst	Accrued Clinical Trial Liability AccruedClinicalTrialLiability	841000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2186000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1589000	usd
CY2022Q2	tpst	Accrued Clinical Trial Liability AccruedClinicalTrialLiability	869000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	748000	usd
CY2021Q4	tpst	Accrued Clinical Trial Liability AccruedClinicalTrialLiability	841000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2186000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1589000	usd
CY2022Q1	tpst	Litigation Expense Amount Covered By Insurance LitigationExpenseAmountCoveredByInsurance	15000000	usd
CY2021Q4	us-gaap	Insurance Settlements Receivable InsuranceSettlementsReceivable	15000000	usd
CY2021Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	15000000	usd
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	15301000	usd
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent	2000000	usd
CY2022Q1	tpst	Litigation Expense Amount Covered By Insurance LitigationExpenseAmountCoveredByInsurance	15000000	usd
CY2021Q4	us-gaap	Insurance Settlements Receivable InsuranceSettlementsReceivable	15000000	usd
CY2021Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	15000000	usd
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	15301000	usd
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent	2000000	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	13301000	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	13301000	usd
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	135936731	shares
CY2021Q2	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	135936731	shares
CY2021Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	114686731	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	114686731	shares
CY2021Q2	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	100187000	usd
CY2020Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	100187000	usd
CY2020	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	99414000	usd
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	99414000	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	135936731	shares
CY2021Q2	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	135936731	shares
CY2021Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	114686731	shares
CY2021Q2	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	100187000	usd
CY2020	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	99414000	usd
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	99414000	usd
CY2021Q2	us-gaap	Redeemable Noncontrolling Interest Equity Preferred Carrying Amount RedeemableNoncontrollingInterestEquityPreferredCarryingAmount	86706000	usd
CY2020Q4	us-gaap	Redeemable Noncontrolling Interest Equity Preferred Carrying Amount RedeemableNoncontrollingInterestEquityPreferredCarryingAmount	86706000	usd
CY2021Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5365899	shares
CY2021Q2	tpst	Stockholders Equity Note Stock Split Exchange Ratio StockholdersEquityNoteStockSplitExchangeRatio	0.0322
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q2	us-gaap	Redeemable Noncontrolling Interest Equity Preferred Carrying Amount RedeemableNoncontrollingInterestEquityPreferredCarryingAmount	86706000	usd
CY2020Q4	us-gaap	Redeemable Noncontrolling Interest Equity Preferred Carrying Amount RedeemableNoncontrollingInterestEquityPreferredCarryingAmount	86706000	usd
CY2021Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5365899	shares
CY2021Q2	tpst	Stockholders Equity Note Stock Split Exchange Ratio StockholdersEquityNoteStockSplitExchangeRatio	0.0322
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10325359	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	790637	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	32.82
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	893527	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10325359	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6910324	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	1.10
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	790637	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	32.82
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	893527	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.36
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.36
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	34703	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	428.76
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1649461	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.72
	tpst	Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Reverse Recapitalization In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod	178732	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.60
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	6316	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	18.36
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1649461	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y10D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.72
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	34703	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	428.76
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1649461	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.72
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	452165	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.35
	tpst	Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Reverse Recapitalization In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod	178732	shares
	tpst	Share Based Compensation Arrangements By Share Based Payment Award Optionsassumed In Reverse Recapitalization In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice	178.64
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	186482	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	20.99
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	10654	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.60
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	6316	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	18.36
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	800409	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	47.70
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1649461	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1649461	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y10D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.72
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1649461	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P9Y10D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	8.72
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	367000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	411000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	695000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P9Y10D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	8.72
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	417033	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y10M2D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	15.91
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	367000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	411000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	695000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	531000	usd
CY2021Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	937300	shares
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	531000	usd
CY2022Q2	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	37000	usd
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	61000	usd
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	usd
CY2021Q2	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-9168000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-7058000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17659000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12413000	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	11573432	shares
CY2022Q2	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	37000	usd
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	61000	usd
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	usd
CY2021Q2	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-9168000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-7058000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17659000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12413000	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	11573432	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	733679	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	0	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	11868	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	9382515	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	733679	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	0	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	11868	shares
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	16061	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11573432	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11573432	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	925432	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	925432	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9382515	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9382515	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	717618	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	717618	shares
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.79
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.63
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	0	shares
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	16061	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11573432	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11573432	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	925432	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	925432	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9382515	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9382515	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	717618	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	717618	shares
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.79
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.63
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.63
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.88
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.88
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-17.30
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.63
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.88
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.88
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-17.30
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-17.30
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1655497	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	802606	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-17.30
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	802606	shares

Files In Submission

Name	View Source	Status
0001628280-22-022788-index-headers.html	Edgar Link	pending
0001628280-22-022788-index.html	Edgar Link	pending
0001628280-22-022788.txt	Edgar Link	pending
0001628280-22-022788-xbrl.zip	Edgar Link	pending
agreementforterminationofl.htm	Edgar Link	pending
exhibit31121.htm	Edgar Link	pending
exhibit31221.htm	Edgar Link	pending
exhibit32121.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tpst-20220630.htm	Edgar Link	pending
tpst-20220630.xsd	Edgar Link	pending
tpst-20220630_lab.xml	Edgar Link	unprocessable
tpst-20220630_def.xml	Edgar Link	unprocessable
tpst-20220630_pre.xml	Edgar Link	unprocessable
tpst-20220630_htm.xml	Edgar Link	completed
tpst-20220630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TPST
Tempest Therapeutics, Inc. Stock $tpst

2022 Q3 Form 10-Q Financial Statement

#000162828022022788 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST Tempest Therapeutics, Inc. Stock $tpst

2022 Q3 Form 10-Q Financial Statement

#000162828022022788 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST
Tempest Therapeutics, Inc. Stock $tpst